Seelos Therapeutics, Inc. (SEEL) News

Seelos Therapeutics, Inc. (SEEL): $0.59

0.02 (+4.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SEEL to Watchlist
Sign Up

Industry: Biotech


Ranked

of 392

in industry

Filter SEEL News Items

SEEL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SEEL News Highlights

  • For SEEL, its 30 day story count is now at 5.
  • Over the past 21 days, the trend for SEEL's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • ATAI, CMPS and MNMD are the most mentioned tickers in articles about SEEL.

Latest SEEL News From Around the Web

Below are the latest news stories about Seelos Therapeutics Inc that investors may wish to consider to help them evaluate SEEL as an investment opportunity.

Psychedelic Stock Gainers And Losers From February 24, 2022

GAINERS: Seelos Therapeutics (NASDAQ: SEEL ) shares closed up 11.06% at $1.10 Mind Medicine (NASDAQ: MNMD ) shares closed up 11.01% at $1.21 Compass Pathways (NASDAQ: CMPS ) shares closed up 4.50% at $13.23 ATAI Life Sciences (NASDAQ: ATAI ) shares closed up 3.83% at $5.42 Mindset Pharma (OTC: Full story available on Benzinga.com

Benzinga | February 24, 2022

B.Riley Financial Thinks Seelos Therapeutics’ Stock is Going to Recover

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Seelos Therapeutics (SEEL – Research Report) today and set a price target of $6.00. The company's shares closed last Wednesday at $1.20, close to its 52-week low of $1.00. According to TipRanks.com, Mamtani has 0 stars on 0-5 stars ranking scale with an average return of -19.6% and a 28.4% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals. Seelos Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.

Howard Kim on TipRanks | February 17, 2022

Field Trip Health, Seelos Therapeutics Among Top Psychedelic Movers Of Today

GAINERS: Small Pharma (OTC: Full story available on Benzinga.com

Benzinga | February 3, 2022

Psychedelic Stock Gainers And Losers From January 20, 2022

GAINERS: Small Pharma (OTC: DMTTF ) shares closed up 14.55% at $0.21 GH Research (NASDAQ: GHRS ) shares closed up 3.35% at $16.99 Field Trip Health (NASDAQ: FTRP ) shares closed up 2.00% at $2.04 LOSERS: Mindset Pharma (OTC: MSSTF ) shares closed down -4.33% at $0.57 Seelos Therapeutics (NASDAQ: SEEL ) shares closed down Full story available on Benzinga.com

Benzinga | January 20, 2022

Seelos Therapeutics, Inc. (NASDAQ:SEEL) Expected to Post Earnings of -$0.12 Per Share

Brokerages forecast that Seelos Therapeutics, Inc. (NASDAQ:SEEL) will report earnings per share of ($0.12) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Seelos Therapeutics earnings. The highest EPS estimate is ($0.11) and the lowest is ($0.12). Seelos Therapeutics posted earnings per share of ($0.13) during the same []

Dakota Financial News | December 23, 2021

Zacks: Brokerages Anticipate Seelos Therapeutics, Inc. (NASDAQ:SEEL) to Announce -$0.12 EPS

Brokerages expect Seelos Therapeutics, Inc. (NASDAQ:SEEL) to report earnings per share (EPS) of ($0.12) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Seelos Therapeutics earnings. The lowest EPS estimate is ($0.12) and the highest is ($0.11). Seelos Therapeutics reported earnings of ($0.13) per share during the same quarter []

Transcript Daily | December 21, 2021

Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Dec. 21, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has granted

Business Insider Markets | December 21, 2021

Seelos Therapeutics to Participate in the 11th Annual LifeSci Partners Corporate Access Event

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 11th Annual LifeSci Partners Corporate Access Event, January 5-7th, 2022.

Yahoo | December 16, 2021

Seelos Therapeutics Inc. (NASDAQ: SEEL) Stock Forecast: Potential To Pass $14.00 Within A Year

The trading price of Seelos Therapeutics Inc. (NASDAQ:SEEL) closed lower on Monday, December 13, closing at $1.70, -1.73% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Stocks Register | December 14, 2021

Seelos Therapeutics secures composition of matter patent in Japan for SLS-007

No summary available.

Seeking Alpha | December 6, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5367 seconds.